#BEGIN_DRUGCARD DB01278

# AHFS_Codes:
Not Available

# ATC_Codes:
A10BX05

# Absorption:
The absolute bioavailability of a single subcutaneous dose of pramlintide is approximately 30 to 40%.

# Biotransformation:
Metabolized primarily by the kidneys.

# Brand_Mixtures:
Not Available

# Brand_Names:
Symlin

# CAS_Registry_Number:
151126-32-8

# ChEBI_ID:
Not Available

# Chemical_Formula:
C171H267N51O53S2

# Chemical_IUPAC_Name:
Not Available

# Chemical_Structure:
>Pramlintide
KCNTATCATNRLANFLVHSSNNFGPILPPTNVGSNTY

# Creation_Date:
2007-05-16 16:15:59 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.

# Dosage_Forms:
Solution	Subcutaneous

# Drug_Category:
Not Available

# Drug_Interactions:
Aclidinium	May increase the risk of inhibition of GI motility via pharmacodynamic synergism. Consider alternate therapy.
Carbinoxamine	Pramlintide may enhance the anticholinergic effect of Anticholinergics such as carbinoxamine. These effects are specific to the gastrointestinal tract. Use caution during concomitant therapy with pramlintide and anticholinergics. Additive effects on reduced gastrointestinal motility may occur.
Clidinium	Pramlintide may enhance the anticholinergic effect of anticholinergics such as clidinium. These effects are specific to the GI tract. Use caution during concomitant therapy with pramlintide and anticholinergics. Additive effects on reduced GI motility may occur.
Doxylamine	May cause additive slowing of GI motility.
Thiothixene	The anticholinergic effects of Tranylcypromine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
Tiotropium	The anticholinergic effects of Tiotropium may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
Tolterodine	Additive reduction in gut motility may occur. Consider alternate therapy or use caution during concomitant therapy.
Tranylcypromine	The anticholinergic effects of Tranylcypromine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
Trihexyphenidyl	The anticholinergic effects of Trihexyphenidyl may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
Trimeprazine	The anticholinergic effects of Trimeprazine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
Trimethobenzamide	The anticholinergic effects of Trimethobenzamide may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
Trimipramine	The anticholinergic effects of Trimipramine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
Triprolidine	The anticholinergic effects of Triprolidine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
Trospium	The anticholinergic effects of Trospium may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
Zuclopenthixol	May cause additive reduction in GI motility. Use caution or consider alternate therapy.

# Drug_Reference:
12841822	Kleppinger EL, Vivian EM: Pramlintide for the treatment of diabetes mellitus. Ann Pharmacother. 2003 Jul-Aug;37(7-8):1082-9.
16330288	Ryan GJ, Jobe LJ, Martin R: Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther. 2005 Oct;27(10):1500-12.
17619527	Jones MC: Therapies for diabetes: pramlintide and exenatide. Am Fam Physician. 2007 Jun 15;75(12):1831-5.
18998755	Edelman S, Maier H, Wilhelm K: Pramlintide in the treatment of diabetes mellitus. BioDrugs. 2008;22(6):375-86. doi: 10.2165/0063030-200822060-00004.

# Drug_Type:
Approved
Biotech
Investigational

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Pramlintide

# HET_ID:
Not Available

# Half_Life:
Approximately 48 minutes

# InChI_Identifier:
Not Available

# InChI_Key:
Not Available

# Indication:
For the treatment of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D05595

# LIMS_Drug_ID:
1278

# Mechanism_Of_Action:
Pramlintide is an amlyinomimetic, a functional analog of the naturally occurring pancreatic hormone amylin. Amylin has activity in a number of gastrointestinal and glucodynamic systems, and by mimicking its activity, pramlintide acts to improve glycemic control through modulation of the rate of gastric emptying, prevention of post-prandial rise in glucagon levels, and by increasing sensations of satiety, thereby reducing caloric intake and potentiating weight loss. There appears to be at least three distinct receptor complexes that bind with high affinity to amylin. All three complexes contain the calcitonin receptor at the core, plus one of three Receptor activity-modifying proteins, RAMP1, RAMP2, or RAMP3.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
3949.3896

# Molecular_Weight_Mono:
Not Available

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164781394

# Pharmacology:
Pramlintide is a synthetic analog of amylin, a glucoregulatory hormone that is synthesized by pancreatic Î²-cells and released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. It is provided as an acetate salt. Pramlintide is a 37-amino acid polypeptide that differs structurally from human amylin by the replacement of alanine, serine, and serine at positions 25, 28, and 29 respectively with proline.

# Predicted_LogP_Hydrophobicity:
Not Available

# Predicted_LogS:
Not Available

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB01278

# Protein_Binding:
Pramlintide does not extensively bind to blood cells or albumin (approximately 40% of the drug is unbound in plasma).

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/cgi/generic/symlin.htm

# Salts:
Pramlintide acetate

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
Not Available

# State:
liquid

# Structure:
0

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2012-04-22 23:06:27 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Pramlintide

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11772274	Nyholm B, Brock B, Orskov L, Schmitz O: Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus. Expert Opin Investig Drugs. 2001 Sep;10(9):1641-52.
15494035	Hay DL, Christopoulos G, Christopoulos A, Sexton PM: Amylin receptors: molecular composition and pharmacology. Biochem Soc Trans. 2004 Nov;32(Pt 5):865-7.
19273748	Roth JD, Maier H, Chen S, Roland BL: Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications. Arch Neurol. 2009 Mar;66(3):306-10.
20015292	Qi T, Hay DL: Structure-function relationships of the N-terminus of receptor activity-modifying proteins. Br J Pharmacol. 2010 Mar;159(5):1059-68. Epub 2009 Dec 10.
20357016	Lutz TA: The role of amylin in the control of energy homeostasis. Am J Physiol Regul Integr Comp Physiol. 2010 Jun;298(6):R1475-84. Epub 2010 Mar 31.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
CALCR

# Drug_Target_1_GenBank_ID_Gene:
L00587

# Drug_Target_1_GenBank_ID_Protein:
179880

# Drug_Target_1_GeneCard_ID:
CALCR

# Drug_Target_1_Gene_Name:
CALCR

# Drug_Target_1_Gene_Sequence:
>1473 bp
ATGAGGTTCACATTTACAAGCCGGTGCTTGGCACTGTTTCTTCTTCTAAATCACCCAACC
CCAATTCTTCCTGCCTTTTCAAATCAAACCTATCCAACAATAGAGCCCAAGCCATTTCTT
TACGTCGTAGGACGAAAGAAGATGATGGATGCACAGTACAAATGCTATGACCGAATGCAG
CAGTTACCCGCATACCAAGGAGAAGGTCCATATTGCAATCGCACCTGGGATGGATGGCTG
TGCTGGGATGACACACCGGCTGGAGTATTGTCCTATCAGTTCTGCCCAGATTATTTTCCG
GATTTTGATCCATCAGAAAAGGTTACAAAATACTGTGATGAAAAAGGTGTTTGGTTTAAA
CATCCTGAAAACAATCGAACCTGGTCCAACTATACTATGTGCAATGCTTTCACTCCTGAG
AAACTGAAGAATGCATATGTTCTGTACTATTTGGCTATTGTGGGTCATTCTTTGTCAATT
TTCACCCTAGTGATTTCCCTGGGGATTTTCGTGTTTTTCAGAAAATTGACAACTATTTTT
CCTTTGAATTGGAAATATAGGAAGGCATTGAGCCTTGGCTGCCAAAGGGTAACCCTGCAC
AAGAACATGTTTCTTACTTACATTCTGAATTCTATGATTATCATCATCCACCTGGTTGAA
GTAGTACCCAATGGAGAGCTCGTGCGAAGGGACCCGGTGAGCTGCAAGATTTTGCATTTT
TTCCACCAGTACATGATGGCCTGCAACTATTTCTGGATGCTCTGTGAAGGGATCTATCTT
CATACACTCATTGTCGTGGCTGTGTTTACTGAGAAGCAACGCTTGCGGTGGTATTATCTC
TTGGGCTGGGGGTTCCCGCTGGTGCCAACCACTATCCATGCTATTACCAGGGCCGTGTAC
TTCAATGACAACTGCTGGCTGAGTGTGGAAACCCATTTGCTTTACATAATCCATGGACCT
GTCATGGCGGCACTTGTGGTCAATTTCTTCTTTTTGCTCAACATTGTCCGGGTGCTTGTG
ACCAAAATGAGGGAAACCCATGAGGCGGAATCCCACATGTACCTGAAGGCTGTGAAGGCC
ACCATGATCCTTGTGCCCCTGCTGGGAATCCAGTTTGTCGTCTTTCCCTGGAGACCTTCC
AACAAGATGCTTGGGAAGATATATGATTACGTGATGCACTCTCTGATTCATTTCCAGGGC
TTCTTTGTTGCGACCATCTACTGCTTCTGCAACAATGAGGTCCAAACCACCGTGAAGCGC
CAATGGGCCCAATTCAAAATTCAGTGGAACCAGCGTTGGGGGAGGCGCCCCTCCAACCGC
TCTGCTCGCGCTGCAGCCGCTGCTGCGGAGGCTGGCGACATCCCAATTTACATCTGCCAT
CAGGAGCCGAGGAATGAACCAGCCAACAACCAAGGCGAGGAGAGTGCTGAGATCATCCCT
TTGAATATCATAGAGCAAGAGTCATCTGCTTGA

# Drug_Target_1_General_Function:
Involved in calcitonin receptor activity

# Drug_Target_1_General_References:
10570950	Nishikawa T, Ishikawa H, Yamamoto S, Koshihara Y: A novel calcitonin receptor gene in human osteoclasts from normal bone marrow. FEBS Lett. 1999 Sep 24;458(3):409-14.
12853948	Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C, Layman D, Maas J, Jaeger S, Walker R, Wylie K, Sekhon M, Becker MC, O'Laughlin MD, Schaller ME, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Cordes M, Du H, Sun H, Edwards J, Bradshaw-Cordum H, Ali J, Andrews S, Isak A, Vanbrunt A, Nguyen C, Du F, Lamar B, Courtney L, Kalicki J, Ozersky P, Bielicki L, Scott K, Holmes A, Harkins R, Harris A, Strong CM, Hou S, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Leonard S, Rohlfing T, Rock SM, Tin-Wollam AM, Abbott A, Minx P, Maupin R, Strowmatt C, Latreille P, Miller N, Johnson D, Murray J, Woessner JP, Wendl MC, Yang SP, Schultz BR, Wallis JW, Spieth J, Bieri TA, Nelson JO, Berkowicz N, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Bedell JA, Mardis ER, Clifton SW, Chissoe SL, Marra MA, Raymond C, Haugen E, Gillett W, Zhou Y, James R, Phelps K, Iadanoto S, Bubb K, Simms E, Levy R, Clendenning J, Kaul R, Kent WJ, Furey TS, Baertsch RA, Brent MR, Keibler E, Flicek P, Bork P, Suyama M, Bailey JA, Portnoy ME, Torrents D, Chinwalla AT, Gish WR, Eddy SR, McPherson JD, Olson MV, Eichler EE, Green ED, Waterston RH, Wilson RK: The DNA sequence of human chromosome 7. Nature. 2003 Jul 10;424(6945):157-64.
1331173	Gorn AH, Lin HY, Yamin M, Auron PE, Flannery MR, Tapp DR, Manning CA, Lodish HF, Krane SM, Goldring SR: Cloning, characterization, and expression of a human calcitonin receptor from an ovarian carcinoma cell line. J Clin Invest. 1992 Nov;90(5):1726-35.
7588285	Albrandt K, Brady EM, Moore CX, Mull E, Sierzega ME, Beaumont K: Molecular cloning and functional expression of a third isoform of the human calcitonin receptor and partial characterization of the calcitonin receptor gene. Endocrinology. 1995 Dec;136(12):5377-84.
7720653	Nussenzveig DR, Mathew S, Gershengorn MC: Alternative splicing of a 48-nucleotide exon generates two isoforms of the human calcitonin receptor. Endocrinology. 1995 May;136(5):2047-51.
7733946	Nakamura M, Hashimoto T, Nakajima T, Ichii S, Furuyama J, Ishihara Y, Kakudo K: A new type of human calcitonin receptor isoform generated by alternative splicing. Biochem Biophys Res Commun. 1995 Apr 17;209(2):744-51.
8078488	Kuestner RE, Elrod RD, Grant FJ, Hagen FS, Kuijper JL, Matthewes SL, O'Hara PJ, Sheppard PO, Stroop SD, Thompson DL, et al.: Cloning and characterization of an abundant subtype of the human calcitonin receptor. Mol Pharmacol. 1994 Aug;46(2):246-55.
8143880	Frendo JL, Pichaud F, Mourroux RD, Bouizar Z, Segond N, Moukhtar MS, Jullienne A: An isoform of the human calcitonin receptor is expressed in TT cells and in medullary carcinoma of the thyroid. FEBS Lett. 1994 Apr 4;342(2):214-6.
9817931	Taboulet J, Frenkian M, Frendo JL, Feingold N, Jullienne A, de Vernejoul MC: Calcitonin receptor polymorphism is associated with a decreased fracture risk in post-menopausal women. Hum Mol Genet. 1998 Dec;7(13):2129-33.

# Drug_Target_1_HGNC_ID:
HGNC:1440

# Drug_Target_1_HPRD_ID:
00239

# Drug_Target_1_ID:
479

# Drug_Target_1_Locus:
7q21.3

# Drug_Target_1_Molecular_Weight:
57304

# Drug_Target_1_Name:
Calcitonin receptor

# Drug_Target_1_Number_of_Residues:
490

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00002	7tm_2
PF02793	HRM

# Drug_Target_1_Protein_Sequence:
>Calcitonin receptor precursor
MRFTFTSRCLALFLLLNHPTPILPAFSNQTYPTIEPKPFLYVVGRKKMMDAQYKCYDRMQ
QLPAYQGEGPYCNRTWDGWLCWDDTPAGVLSYQFCPDYFPDFDPSEKVTKYCDEKGVWFK
HPENNRTWSNYTMCNAFTPEKLKNAYVLYYLAIVGHSLSIFTLVISLGIFVFFRKLTTIF
PLNWKYRKALSLGCQRVTLHKNMFLTYILNSMIIIIHLVEVVPNGELVRRDPVSCKILHF
FHQYMMACNYFWMLCEGIYLHTLIVVAVFTEKQRLRWYYLLGWGFPLVPTTIHAITRAVY
FNDNCWLSVETHLLYIIHGPVMAALVVNFFFLLNIVRVLVTKMRETHEAESHMYLKAVKA
TMILVPLLGIQFVVFPWRPSNKMLGKIYDYVMHSLIHFQGFFVATIYCFCNNEVQTTVKR
QWAQFKIQWNQRWGRRPSNRSARAAAAAAEAGDIPIYICHQEPRNEPANNQGEESAEIIP
LNIIEQESSA

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-24

# Drug_Target_1_Specific_Function:
This is a receptor for calcitonin. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. The calcitonin receptor is thought to couple to the heterotrimeric guanosine triphosphate-binding protein that is sensitive to cholera toxin

# Drug_Target_1_SwissProt_ID:
P30988

# Drug_Target_1_SwissProt_Name:
CALCR_HUMAN

# Drug_Target_1_Synonyms:
CT-R
Calcitonin receptor precursor

# Drug_Target_1_Theoretical_pI:
8.71

# Drug_Target_1_Transmembrane_Regions:
154-173
197-216
237-259
277-296
313-336
360-377
390-411

# Drug_Target_2_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
11772274	Nyholm B, Brock B, Orskov L, Schmitz O: Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus. Expert Opin Investig Drugs. 2001 Sep;10(9):1641-52.
15494035	Hay DL, Christopoulos G, Christopoulos A, Sexton PM: Amylin receptors: molecular composition and pharmacology. Biochem Soc Trans. 2004 Nov;32(Pt 5):865-7.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
18593822	Qi T, Christopoulos G, Bailey RJ, Christopoulos A, Sexton PM, Hay DL: Identification of N-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, adrenomedullin, and amylin receptor function. Mol Pharmacol. 2008 Oct;74(4):1059-71. Epub 2008 Jul 1.
19273748	Roth JD, Maier H, Chen S, Roland BL: Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications. Arch Neurol. 2009 Mar;66(3):306-10.
20015292	Qi T, Hay DL: Structure-function relationships of the N-terminus of receptor activity-modifying proteins. Br J Pharmacol. 2010 Mar;159(5):1059-68. Epub 2009 Dec 10.
20357016	Lutz TA: The role of amylin in the control of energy homeostasis. Am J Physiol Regul Integr Comp Physiol. 2010 Jun;298(6):R1475-84. Epub 2010 Mar 31.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
RAMP1

# Drug_Target_2_GenBank_ID_Gene:
AJ001014

# Drug_Target_2_GenBank_ID_Protein:
3171910

# Drug_Target_2_GeneCard_ID:
RAMP1

# Drug_Target_2_Gene_Name:
RAMP1

# Drug_Target_2_Gene_Sequence:
>447 bp
ATGGCCCGGGCCCTGTGCCGCCTCCCGCGGCGCGGCCTCTGGCTGCTCCTGGCCCATCAC
CTCTTCATGACCACTGCCTGCCAGGAGGCTAACTACGGTGCCCTCCTCCGGGAGCTCTGC
CTCACCCAGTTCCAGGTAGACATGGAGGCCGTCGGGGAGACGCTGTGGTGTGACTGGGGC
AGGACCATCAGGAGCTACAGGGAGCTGGCCGACTGCACCTGGCACATGGCGGAGAAGCTG
GGCTGCTTCTGGCCCAATGCAGAGGTGGACAGGTTCTTCCTGGCAGTGCATGGCCGCTAC
TTCAGGAGCTGCCCCATCTCAGGCAGGGCCGTGCGGGACCCGCCCGGCAGCATCCTCTAC
CCCTTCATCGTGGTCCCCATCACGGTGACCCTGCTGGTGACGGCACTGGTGGTCTGGCAG
AGCAAGCGCACTGAGGGCATTGTGTAG

# Drug_Target_2_General_Function:
Involved in protein transporter activity

# Drug_Target_2_General_References:
9620797	McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM: RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998 May 28;393(6683):333-9.

# Drug_Target_2_HGNC_ID:
HGNC:9843

# Drug_Target_2_HPRD_ID:
05515

# Drug_Target_2_ID:
959

# Drug_Target_2_Locus:
2q36-q37.1

# Drug_Target_2_Molecular_Weight:
16988

# Drug_Target_2_Name:
Receptor activity-modifying protein 1

# Drug_Target_2_Number_of_Residues:
148

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF04901	RAMP

# Drug_Target_2_Protein_Sequence:
>Receptor activity-modifying protein 1 precursor
MARALCRLPRRGLWLLLAHHLFMTTACQEANYGALLRELCLTQFQVDMEAVGETLWCDWG
RTIRSYRELADCTWHMAEKLGCFWPNAEVDRFFLAVHGRYFRSCPISGRAVRDPPGSILY
PFIVVPITVTLLVTALVVWQSKRTEGIV

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-26

# Drug_Target_2_Specific_Function:
Transports the calcitonin gene-related peptide type 1 receptor (CALCRL) to the plasma membrane. Acts as a receptor for calcitonin-gene-related peptide (CGRP) together with CALCRL

# Drug_Target_2_SwissProt_ID:
O60894

# Drug_Target_2_SwissProt_Name:
RAMP1_HUMAN

# Drug_Target_2_Synonyms:
CRLR activity- modifying protein 1
Calcitonin-receptor-like receptor activity- modifying protein 1
Receptor activity-modifying protein 1 precursor

# Drug_Target_2_Theoretical_pI:
8.29

# Drug_Target_2_Transmembrane_Regions:
118-138

# Drug_Target_3_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
15494035	Hay DL, Christopoulos G, Christopoulos A, Sexton PM: Amylin receptors: molecular composition and pharmacology. Biochem Soc Trans. 2004 Nov;32(Pt 5):865-7.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
18593822	Qi T, Christopoulos G, Bailey RJ, Christopoulos A, Sexton PM, Hay DL: Identification of N-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, adrenomedullin, and amylin receptor function. Mol Pharmacol. 2008 Oct;74(4):1059-71. Epub 2008 Jul 1.
19273748	Roth JD, Maier H, Chen S, Roland BL: Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications. Arch Neurol. 2009 Mar;66(3):306-10.
20015292	Qi T, Hay DL: Structure-function relationships of the N-terminus of receptor activity-modifying proteins. Br J Pharmacol. 2010 Mar;159(5):1059-68. Epub 2009 Dec 10.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
RAMP2

# Drug_Target_3_GenBank_ID_Gene:
AJ001015

# Drug_Target_3_GenBank_ID_Protein:
3171912

# Drug_Target_3_GeneCard_ID:
RAMP2

# Drug_Target_3_Gene_Name:
RAMP2

# Drug_Target_3_Gene_Sequence:
>528 bp
ATGGCCTCGCTCCGGGTGGAGCGCGCCGGCGGCCCGCGTCTCCCTAGGACCCGAGTCGGG
CGGCCGGCAGCCGTCCGCCTCCTCCTTCTGCTGGGCGCTGTCCTGAATCCCCACGAGGCC
CTGGCTCAGCCTCTTCCCACCACAGGCACACCAGGGTCAGAAGGGGGGACGGTGAAGAAC
TATGAGACAGCTGTCCAATTTTGCTGGAATCATTATAAGGATCAAATGGATCCTATCGAA
AAGGATTGGTGCGACTGGGCCATGATTAGCAGGCCTTATAGCACCCTGCGAGATTGCCTG
GAGCACTTTGCAGAGTTGTTTGACCTGGGCTTCCCCAATCCCTTGGCAGAGAGGATCATC
TTTGAGACTCACCAGATCCACTTTGCCAACTGCTCCCTGGTGCAGCCCACCTTCTCTGAC
CCCCCAGAGGATGTACTCCTGGCCATGATCATAGCCCCCATCTGCCTCATCCCCTTCCTC
ATCACTCTTGTAGTATGGAGGAGTAAAGACAGTGAGGCCCAGGCCTAG

# Drug_Target_3_General_Function:
Involved in protein transporter activity

# Drug_Target_3_General_References:
9620797	McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM: RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998 May 28;393(6683):333-9.

# Drug_Target_3_HGNC_ID:
HGNC:9844

# Drug_Target_3_HPRD_ID:
05516

# Drug_Target_3_ID:
960

# Drug_Target_3_Locus:
17q12-q21.1

# Drug_Target_3_Molecular_Weight:
19608

# Drug_Target_3_Name:
Receptor activity-modifying protein 2

# Drug_Target_3_Number_of_Residues:
175

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF04901	RAMP

# Drug_Target_3_Protein_Sequence:
>Receptor activity-modifying protein 2 precursor
MASLRVERAGGPRLPRTRVGRPAALRLLLLLGAVLNPHEALAQPLPTTGTPGSEGGTVKN
YETAVQFCWNHYKDQMDPIEKDWCDWAMISRPYSTLRDCLEHFAELFDLGFPNPLAERII
FETHQIHFANCSLVQPTFSDPPEDVLLAMIIAPICLIPFLITLVVWRSKDSEAQA

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
1-42

# Drug_Target_3_Specific_Function:
Transports the calcitonin gene-related peptide type 1 receptor (CALCRL) to the plasma membrane. Acts as a receptor for adrenomedullin (AM) together with CALCRL

# Drug_Target_3_SwissProt_ID:
O60895

# Drug_Target_3_SwissProt_Name:
RAMP2_HUMAN

# Drug_Target_3_Synonyms:
CRLR activity- modifying protein 2
Calcitonin-receptor-like receptor activity- modifying protein 2
Receptor activity-modifying protein 2 precursor

# Drug_Target_3_Theoretical_pI:
5.58

# Drug_Target_3_Transmembrane_Regions:
146-166

# Drug_Target_4_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
11772274	Nyholm B, Brock B, Orskov L, Schmitz O: Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus. Expert Opin Investig Drugs. 2001 Sep;10(9):1641-52.
15494035	Hay DL, Christopoulos G, Christopoulos A, Sexton PM: Amylin receptors: molecular composition and pharmacology. Biochem Soc Trans. 2004 Nov;32(Pt 5):865-7.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
18593822	Qi T, Christopoulos G, Bailey RJ, Christopoulos A, Sexton PM, Hay DL: Identification of N-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, adrenomedullin, and amylin receptor function. Mol Pharmacol. 2008 Oct;74(4):1059-71. Epub 2008 Jul 1.
19273748	Roth JD, Maier H, Chen S, Roland BL: Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications. Arch Neurol. 2009 Mar;66(3):306-10.
20015292	Qi T, Hay DL: Structure-function relationships of the N-terminus of receptor activity-modifying proteins. Br J Pharmacol. 2010 Mar;159(5):1059-68. Epub 2009 Dec 10.
20357016	Lutz TA: The role of amylin in the control of energy homeostasis. Am J Physiol Regul Integr Comp Physiol. 2010 Jun;298(6):R1475-84. Epub 2010 Mar 31.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
RAMP3

# Drug_Target_4_GenBank_ID_Gene:
AJ001016

# Drug_Target_4_GenBank_ID_Protein:
3171914

# Drug_Target_4_GeneCard_ID:
RAMP3

# Drug_Target_4_Gene_Name:
RAMP3

# Drug_Target_4_Gene_Sequence:
>447 bp
ATGGAGACTGGAGCGCTGCGGCGCCCGCAACTTCTCCCGTTGCTGCTGCTGCTCTGCGGT
GGGTGTCCCAGAGCAGGCGGCTGCAACGAGACAGGCATGTTGGAGAGGCTGCCCCTGTGT
GGGAAGGCTTTCGCAGACATGATGGGCAAGGTGGACGTCTGGAAGTGGTGCAACCTGTCC
GAGTTCATCGTGTACTATGAGAGTTTCACCAACTGCACCGAGATGGAGGCCAATGTCGTG
GGCTGCTACTGGCCCAACCCCCTGGCCCAGGGCTTCATCACCGGCATCCACAGGCAGTTC
TTCTCCAACTGCACCGTGGACAGGGTCCACTTGGAGGACCCCCCAGACGAGGTTCTCATC
CCGCTGATCGTTATACCCGTCGTTCTGACTGTCGCCATGGCTGGCCTGGTGGTGTGGCGC
AGCAAACGCACCGACACGCTGCTGTGA

# Drug_Target_4_General_Function:
Involved in protein transporter activity

# Drug_Target_4_General_References:
12853948	Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C, Layman D, Maas J, Jaeger S, Walker R, Wylie K, Sekhon M, Becker MC, O'Laughlin MD, Schaller ME, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Cordes M, Du H, Sun H, Edwards J, Bradshaw-Cordum H, Ali J, Andrews S, Isak A, Vanbrunt A, Nguyen C, Du F, Lamar B, Courtney L, Kalicki J, Ozersky P, Bielicki L, Scott K, Holmes A, Harkins R, Harris A, Strong CM, Hou S, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Leonard S, Rohlfing T, Rock SM, Tin-Wollam AM, Abbott A, Minx P, Maupin R, Strowmatt C, Latreille P, Miller N, Johnson D, Murray J, Woessner JP, Wendl MC, Yang SP, Schultz BR, Wallis JW, Spieth J, Bieri TA, Nelson JO, Berkowicz N, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Bedell JA, Mardis ER, Clifton SW, Chissoe SL, Marra MA, Raymond C, Haugen E, Gillett W, Zhou Y, James R, Phelps K, Iadanoto S, Bubb K, Simms E, Levy R, Clendenning J, Kaul R, Kent WJ, Furey TS, Baertsch RA, Brent MR, Keibler E, Flicek P, Bork P, Suyama M, Bailey JA, Portnoy ME, Torrents D, Chinwalla AT, Gish WR, Eddy SR, McPherson JD, Olson MV, Eichler EE, Green ED, Waterston RH, Wilson RK: The DNA sequence of human chromosome 7. Nature. 2003 Jul 10;424(6945):157-64.
9620797	McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM: RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998 May 28;393(6683):333-9.

# Drug_Target_4_HGNC_ID:
HGNC:9845

# Drug_Target_4_HPRD_ID:
05517

# Drug_Target_4_ID:
961

# Drug_Target_4_Locus:
7p13-p12

# Drug_Target_4_Molecular_Weight:
16519

# Drug_Target_4_Name:
Receptor activity-modifying protein 3

# Drug_Target_4_Number_of_Residues:
148

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF04901	RAMP

# Drug_Target_4_Protein_Sequence:
>Receptor activity-modifying protein 3 precursor
METGALRRPQLLPLLLLLCGGCPRAGGCNETGMLERLPLCGKAFADMMGKVDVWKWCNLS
EFIVYYESFTNCTEMEANVVGCYWPNPLAQGFITGIHRQFFSNCTVDRVHLEDPPDEVLI
PLIVIPVVLTVAMAGLVVWRSKRTDTLL

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
1-23

# Drug_Target_4_Specific_Function:
Transports the calcitonin gene-related peptide type 1 receptor (CALCRL) to the plasma membrane. Acts as a receptor for adrenomedullin (AM) together with CALCRL

# Drug_Target_4_SwissProt_ID:
O60896

# Drug_Target_4_SwissProt_Name:
RAMP3_HUMAN

# Drug_Target_4_Synonyms:
CRLR activity- modifying protein 3
Calcitonin-receptor-like receptor activity- modifying protein 3
Receptor activity-modifying protein 3 precursor

# Drug_Target_4_Theoretical_pI:
5.15

# Drug_Target_4_Transmembrane_Regions:
119-138

#END_DRUGCARD DB01278
